Search
  • Cure ATRT

FDA Accepts Drug in Phase 1 study INI1-Negative Tumors, Including AT/RT

Updated: Feb 5


Epizyme, Inc. a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s investigational new drug (IND) application for tazemetostat for the treatment of adults and pediatric patients with INI1-negative tumors or synovial sarcoma. In the second half of 2015, Epizyme plans to initiate a multi-center phase 2 study in adults and a multi-center phase 1 study in children to evaluate tazemetostat in patients with relapsed or refractory INI1-negative tumors or synovial sarcoma.

Read More


0 views

Email us:

info@cureatrt.org

 

  • Facebook - White Circle
  • Twitter - White Circle
  • Facebook - White Circle
  • Twitter - White Circle
  • Tumblr - White Circle

Social:

Cure ATRT

 

Avalanna

 

Write us:

1 Colonial Drive,

Merrimac, MA 01860

 

 

​​​

© 2015 by Cure ATRT Now

Call us:

877-481-3300